GlassScriptPhysician profile
Susan Wolgamott
NPI 1760894638
$327,216.20
in general payments reported to CMS, 2019-2025
31 companies · $58K in 2025
The $58K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28K · 2022: $42K · 2023: $111K · 2024: $89K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $157K · Travel and Lodging: $51K · Consulting Fee: $19K · Food and Beverage: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,100 · Honoraria: $4,313 · Education: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $156,747.36 |
| Travel and Lodging | $51,261.90 |
| Consulting Fee | $18,532.50 |
| Food and Beverage | $16,474.83 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,100.00 |
| Honoraria | $4,312.50 |
| Education | $1,015.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $91,173.89 | 2021-2025 | Gimoti |
| Abbvie INC. | $71,679.56 | 2021-2025 | |
| Janssen Biotech, INC. | $55,958.59 | 2021-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30,161.57 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Lilly USA, LLC | $20,733.38 | 2022-2025 | Omvoh, Mounjaro, Zepbound |
| Madrigal Pharmaceuticals | $17,011.70 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $12,705.87 | 2022-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $9,610.52 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $6,651.81 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $4,616.83 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,583.10 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $1,336.70 | 2021-2023 | Zeposia |
| Pfizer INC. | $1,268.61 | 2021-2024 | |
| Novo Nordisk INC | $927.50 | 2024 | |
| Gilead Sciences, INC. | $330.22 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $225.89 | 2023-2025 | Dupixent |
| Genzyme Corporation | $211.53 | 2023-2025 | |
| Qol Medical, LLC | $177.23 | 2021-2025 | Sucraid |
| Merck Sharp & Dohme LLC | $160.38 | 2021-2023 | Dificid |
| Exact Sciences Corporation | $122.72 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.92 | 2023 | |
| Intercept Pharmaceuticals, INC. | $88.93 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $80.42 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $72.18 | 2023-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $50.32 | 2024-2025 | Bylvay, Iqirvo |
| Alnylam Pharmaceuticals INC. | $50.00 | 2023-2024 | Givlaari |
| Ferring Pharmaceuticals INC. | $45.83 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $20.43 | 2021 | |
| Redhill Biopharma INC. | $19.00 | 2024 | Talicia |
| Endo Pharmaceuticals INC. | $15.54 | 2021 | |
| Mirum Pharmaceuticals, INC. | $15.03 | 2024 | Livmarli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Wolgamott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.